Biohaven Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biohaven Therapeutics sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Biohaven Therapeutics: 16 sponsored US clinical trials, 8 recruiting.
Biohaven Therapeutics sponsors 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Focal Epilepsy, with 2 trials.
Top-decile sponsor footprint
Biohaven Therapeutics ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
16 total, page 1 of 1
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056
Study of BHV-1300 in Graves' Disease
NCT06980649
Study of BHV-1400 in IgA Nephropathy
NCT07054684
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
NCT06425159
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
NCT06529146
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
NCT06603623
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781
BHV-7000 Open-Label Extension Bipolar Mania Study
NCT06423794
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Biohaven Therapeutics pipeline
8 recruiting of 16 indexed (50% open); 4 completed (25%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Focal Epilepsy (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biohaven Therapeutics: open-pipeline peers nationwide
Peers matched on 16 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Biohaven Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Biohaven Therapeutics page
16 registered trials is a research-attention snapshot, not an endorsement of Biohaven Therapeutics or any single study.
- 8 of Biohaven Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Focal Epilepsy is the condition Biohaven Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Focal Epilepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biohaven Therapeutics pipeline card: 16 registered trials from official public datasets.Report a data error.